You are here: Industry Insights > MCC

News List

Exicure Provides Interim Results from Ongoing Phase 1b/2 Clinical Trial of Cavrotolimod (AST-008) drugs
August 10, 2021
Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, is providing an update on the Phase 1b/2 clinical trial of cavrotolimod (AST-008) (NCT03684785).
Anixa Biosciences, Moffitt Cancer Center File IND Application for Ovarian Cancer CAR-T Therapy americanpharmaceuticalreview
March 25, 2021
Anixa Biosciences announced an IND (Investigational New Drug) application for its ovarian cancer CAR-T (Chimeric Antigen Receptor T-cell) therapy has been filed with the U.S. Food and Drug Administration (FDA).
Merck to submit CDF proposal for cancer drug pharmaceutical-technology
November 30, 2017
The UK National Institute for Health and Care Excellence (NICE) has invited Merck to submit a Cancer Drugs Fund (CDF) proposal for its immunotherapy, avelumab, for the treatment of patients with Merkel cell carcinoma (MCC).